Molecular Reference

Category · 14 compounds

Nootropic & mental-health

The focus, mood and anxiety peptides — Semax, Selank, cerebrolysin — used for clean, non-jittery cognition, though most human research stayed in Russia.

If you’re here, you’re probably after one of three things: a focus that actually holds past lunch, a calmer baseline, or a brain that stopped feeling scorched by 2 p.m.

Nootropic and mental-health peptides are short chains of amino acids studied for focus, mood, memory, and anxiety, most of them working through the brain’s own growth signals like BDNF. A few, like Selank, have small human trials behind them. Most lean on decades of Russian research and community reports the big health sites won’t go near. This hub covers the whole cluster honestly; the individual compound pages carry the citations and the fine print.

What people are actually chasing

Strip out the biochemistry and this cluster sells three feelings: clean focus, a calmer nervous system, and words that come easier. People reach for Semax to lock into work without the jaw-clench of a stimulant, and for Selank to do the opposite, taking anxiety down a notch without the fog or the sedation. A lot of users also describe a specific, oddly consistent effect on language: sentences arrive faster, the right word is just there. That “verbal fluency” report is anecdotal, but it surfaces too often to wave off.

Here’s what surprises people coming from the rest of the peptide world: this is the one corner where the needle is optional. Semax and Selank are most often run as nasal sprays, a couple of drops per nostril, a few times a day. (They’re one letter apart, do nearly opposite jobs, and share a delivery method, which is its own small source of confusion.) The spray route isn’t an accident. These peptides clear the body fast, so people redose across the day instead of taking one hit. If you’re sketching out that kind of schedule, the half-life visualizer shows how quickly a compound fades.

The Russian-research problem

The caveat that hangs over this whole cluster: most of the evidence is Russian, and most of the West has never read it. Semax and Selank were built in Soviet and Russian labs, have been used in Russian clinics for decades, and were tested in mostly Russian-language trials that Western medicine has largely never opened, partly a language barrier and partly that nobody funded a replication. So the honest status of these two is neither “unproven” nor “proven.” It’s “studied for years, mostly somewhere the FDA doesn’t look.”

That gap is exactly why the big health sites skip this cluster, and exactly why we cover it. A compound isn’t fringe just because its trials are in the wrong language. But it isn’t validated by Western standards either, and we won’t pretend a stack of untranslated papers equals a large, independent, English-language trial. None of these compounds are FDA-approved. That line stays straight no matter how good the anecdotes sound.

How brain peptides actually work

Most of this cluster pulls the same lever: the brain’s own growth signals, especially BDNF, short for brain-derived neurotrophic factor. Picture BDNF as fertilizer for neurons. It keeps existing brain cells alive under stress and helps them sprout and strengthen the connections they use to talk to each other. In animal studies, Semax and Selank both raise BDNF, and that is the leading explanation for the focus and mood effects people report.

Not every member works this way. Dihexa targets a different system, the HGF/c-Met pathway, to push neurons to build brand-new synapses. Cerebrolysin is meant to imitate the brain’s natural neurotrophic factors wholesale. And Noopept is the odd one out twice over: it nudges the same NGF and BDNF signals, but it’s technically a small-molecule drug, not a true peptide. The cluster’s single most popular “peptide” doesn’t quite qualify as one, and we flag that on its page rather than quietly filing it with the rest.

What the evidence really shows

The most useful thing to know about this cluster is that the evidence is a spread, not a single grade. The members sit at very different levels of proof, and treating them as one blob is how people get misled.

At the stronger end, Selank has small randomized human trials, mostly Russian, reporting it eased generalized anxiety about as well as a benzodiazepine like medazepam, but without the sedation, memory fog, or withdrawal. That is real human data, and it is still early: small samples, one research tradition, no Western replication yet.

Noopept sits in the middle. In a controlled human study, people with mild cognitive impairment improved about as much on Noopept as on piracetam, at roughly a thousandth of the dose. That is a real result in patients. The popular use, making an already-sharp brain sharper, is the part with essentially no trial behind it.

Cerebrolysin is the strange case of lots of data that still doesn’t settle the question. It’s an actual extract of pig brain, enzymatically chopped into small peptides and amino acids, and it has been through dozens of human trials for stroke and dementia. But an independent Cochrane review of those trials found no clear benefit on survival or long-term recovery and noted most were funded by the maker. Plenty of studies, still no clean verdict.

At the speculative end sit Semax’s healthy-adult focus claims (strong in rats, thin in people) and Dihexa, which is rodent-only. There is no human trial at all, and its flagship rat paper now carries a journal expression of concern, which is a real mark against the headline result. New mechanism, animal-stage data, worth reading with your eyes open.

So the honest map is one member with small human trials, one with patient data but not healthy-user data, one with lots of muddy trials, and two still mostly in animals. Same cluster, five different levels of proof.

Who these are for

The nootropic cluster tends to pull in the person grinding through brain fog, a stretch of burnout, or the low-grade anxiety that makes focus impossible in the first place, someone who read that a nasal spray from a Russian lab might help and wants to know what’s real before trying anything. If that’s you, the move is to read each compound at its own evidence level: Selank and Noopept have actual human data behind their headline uses; Semax and Dihexa are riding mostly on animal studies and community reports.

It’s not the cluster for anyone expecting a stimulant-style jolt. These effects are subtle, and the flat “felt nothing” reports are real. And nothing here is FDA-approved or a treatment for an anxiety disorder or a cognitive condition; that is a conversation for an actual clinician, not a peptide vendor.

If you go deeper, two tools keep the practical side honest: the reconstitution calculator handles the powder-to-dose arithmetic for the injectable versions without pretending to recommend a dose, and the mixing compatibility reference flags which combinations people run together and which shouldn’t share a syringe. For the members studied more for brain aging and neuroprotection than day-to-day focus, the stroke-and-dementia end of this cluster, the longevity and mitochondrial peptides are the next-door neighbors, and that same recovery-after-injury thread overlaps with the healing and recovery peptides. The full lineup lives in the main peptide reference.